Beijing GoBroad Boren Hospital

Beijing, China

Beijing Lu Daopei Hospital, wani bangare na Lu Daopei Medical Group mai zaman kansa a Beijing Economic-Technological Development Area, an sanya masa suna daga masanin kimiyya Lu Daopei, wanda aka fi sani da mahaifin dashen kasusuwan bargo na Sin. Kungiyar — daya daga cikin manyan hanyoyin sadarwar dashen kwayoyin bargo mai samar da jini a duniya, wadda ke gudanar da kusan kashi 10% na yawan dashen allogeneic na shekara-shekara na Sin — ta kammala dashenta na 10,000 a Afrilu 2024, wanda aka ce shi ne mafi sauri wata cibiya ta taba cimma wannan matsayi. Asibitin yana kware a leukaemia, lymphoma, da sauran cututtukan kansa na jini, tare da cikakkiyar kulawar dashen kwayoyin bargo.

Beijing, China

Peking University People's Hospital ya bude a 1918 da sunan Peking Central Hospital, shi ne asibiti na farko mai fanni gaba daya a Sin da Sinawa suka gina kuma suka gudanar da kudinsu tun daga farko, kuma a yau shi ne Second Clinical Medical School of Peking University mai gadaje sama da 2,600 da likitoci 1,300 a sansanoninsa. Cibiyarsa ta Institute of Hematology, wadda aka kafa a 1981, ita ce inda masanin kimiyya Lu Daopei ya yi dashen kasusuwan bargo na allogeneic na farko mai nasara a Sin, kuma ta kasance ta farko a matakin kasa a fannin haematology shekaru goma sha daya a jere. Sashen orthopaedics na asibitin, wanda Feng Chuanhan — wanda ya kafa Chinese Orthopaedic Association — ya kafa a 1944, yana da daya daga cikin manyan cibiyoyin ciwon daji na kashi mafi girma a duniya na irinsa.

Shanghai, China

Ruijin Hospital, wanda ke da alaka da Shanghai Jiao Tong University School of Medicine, an kafa shi a 1907 kuma ya girma ya zama babbar cibiyar likitanci ta ilimi mai matsayin Class 3A da gadaje kusan 2,800 a sansanoni uku a Shanghai. Ana yaba masa a duniya a fannin haematology: likitoci-masana kimiyya a Ruijin — ciki har da Wang Zhenyi, Chen Zhu, da Chen Saijuan — sun kirkiro maganin hade na all-trans retinoic acid (ATRA) da arsenic trioxide domin acute promyelocytic leukaemia, wanda ya daga yawan rayuwa na shekaru biyar daga kusan kashi 10% zuwa fiye da kashi 97%, tare da sake fasalin maganin leukaemia a duniya baki daya. Asibitin ya kammala gwajin amincewa na kasa da kasa na DNV DIAS a 2025, wanda kamfanonin inshora sama da kasashe 130 suka amince da shi, kuma yana da shirye-shirye masu karfi a fannin endocrinology da tiyatar hanji mai karancin fasa.

DNV DIAS